期刊
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
卷 14, 期 3, 页码 133-134出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nrgastro.2017.11
关键词
-
资金
- Abbvie
- Takeda
- Vifor Pharma
- Amgen
- Biogaran
- BMS
- Boerhinger-Ingelheim
- Celgene
- Celltrion
- Ferring
- Forward Pharma
- Genentech
- HAC-Pharma
- Hospira
- Index Pharmaceuticals
- Janssen
- Lilly
- Merck
- Mitsubishi
- Norgine
- Pfizer
- Pharmacosmos
- Pilege
- Sandoz
- Therakos
- Tillots
- UCB-pharma
- Vifor
The treatment of IBD is currently suboptimal. Continuous monitoring of patients with IBD, patient engagement and early treatment adjustments are still difficult hurdles. E-Health could be an efficient tool to improve these aspects, but the current evidence for its use in IBD is poor. An integrated cost-effective e-health system supported by a stable legal framework is eagerly needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
